Ascentage rises on progress of olverembatinib for blood cancer treatment

Ascentage Pharma International

05/12/2025 03:51

** Shares of Ascentage Pharma Group International 6855.HK rise 6.8% to HK$65, their highest level since November 27

** Stock on track for the biggest one-day pct gain since August 5

** Ascentage receives clearance from US FDA and European Medicines Agency for a phrase III (POLARIS-1) study of its blood cancer drug olverembatinib

** The POLARIS-1 trial is a global, multicenter, randomized controlled, open-label study designed to evaluate the efficacy and safety of olverembatinib in combination with chemotherapy in newly diagnosed patients with certain types of leukemia

** Stock up 37% YTD; Hang Seng Biotech Index .HSBIO up 78.8%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))